Calprotectin in Antiphospholipid Syndrome

To better understand the mechanisms that drive antiphospholipid syndrome (APS), Dr. Yu Zuo and his team, evaluated the presence of circulating calprotectin (cCLP) to detect any clinical associations or even the mechanistic role among a cohort of primary APS and aPL-positive patients. Dr. Zuo sits down with us this week to discuss whether calprotectin can be a functional biomarker for those with APS thrombocytopenia and what the future holds for this study’s conclusions.